Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

https://www.soho2019.com/

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Avatar

HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Younger AML Patients with Adverse Biology Routinely Receive It?

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jeffrey Lancet
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Jeffrey Lancet
41 views
October 18, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

16:51
Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison
Acute Myeloid Leukemia
15:38

2019 AML State of the Art Update: How to Treat Newly Diagnosed and S…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

S. Luger

448 views
16:27

CAR T-Cells in AML: An Effective Therapy Requires Optimization of th…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

E. Budde

32 views
13:57

Novel Strategies in High Risk AML: Clinical and Molecular Features

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

J. Welch

19 views
16:06

Chemotherapy-Free Approach in Relapsed/Refractory AML: Antibody-Drug…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

J. DiPersio

313 views
15:39

All Older AML Patients and Younger Patients with Adverse Biology Sho…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

D. Pollyea

1.0K views
17:20

HMA/Ventoclax vs. 3+7/Standard Induction - Should All Older and Youn…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

J. Lancet

41 views
15:19

Use of MRD in AML: Determining Method, Acceptable Endpoint and Progn…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

P. Montesinos

19 views
14:52

How to Choose a FLT3 inhibitor in AML in 2019: Discussion on Midosta…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

C. Smith

41 views
15:52

Use of Gemtuzumab in CD33 + AML: Benefit May Be Greatest in Favorabl…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

R. Walter

18 views
08:26

Synergistic Activity of the MCL-1 Inhibitor S63845 with Midostaurin …

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

A. Skwarska

21 views
09:44

The Promising Data on Efficacy of Mutant IDH1 Inhibitor Ivosidenib (…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

C. DiNardo

26 views
08:59

Genome-Wide CRISPR-Cas9 Screen Identifies XPO7 as a Novel Therapeuti…

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Y. Semba

10 views